KARZINOGENESE-INHIBITOR

Patent europeic · EP3639821 · Stritgà

Inscripziun en il register

Numer da publicaziun
EP3639821
Numer da la dumonda
EP18816986
Gener
Patent europeic cun effect per la Svizra ed il Liechtenstein
Status
Stritgà
Scrittira da patent
Concedì
Annunzià
12-06-2018
Publitgà
22-04-2020
Concedì
28-08-2024
Stritgà
27-01-2026
Motiv
Taxa annuala betg pajada
Classas IPC
A61K 31/4166 (2006.01)
A23L 33/10 (2016.01)
A61P 35/00 (2006.01)
A61P 43/00 (2006.01)
Prioritad
JP 2017115610 13.06.2017
Dumonda PCT
PCT/JP2018/022333 12.06.2018
Publicaziun PCT
WO2018/230537 20.12.2018
Lingua da l’annunzia
giapunais
Funtauna
Swissreg

Istorgia

Quai che l’Institut federal da la proprietad intellectuala ha publitgà davart quest titel, il pli nov l’emprim.

  1. 27-01-2026

    Stritgà, taxa betg pajada

    Status of protective title
    Active → Cancelled
    Cancellation date
    27.01.2026
    Cause for cancellation
    Non-payment of renewal fee

    Published in Swissreg on 27.01.2026

  2. 09-07-2025

    Midada

    Published in Swissreg on 09.07.2025

  3. 28-08-2024

    Concedì

    Specification status
    Non-published patent application → Granted patent
    Status of protective title
    Initiated → Active

    Published in Swissreg on 28.08.2024

Partidas

Possessur

National Cancer Center

5-1-1, Tsukiji Chuo-ku, Tokyo 104-0045, JP

Nippon Zoki Pharmaceutical Co. Ltd

Nippon Zoki Pharmaceutical Co., Ltd.

2-3, Hiranomachi 4-chome, Chuo-ku Osaka-shi, Osaka 541-0046, JP

Inventur

MIYAMOTO, Shingo

Tokyo 104-0045, JP

KUROKAWA, Yurie

Tokyo 104-0045, JP

MUTOH, Michihiro

Tokyo 104-0045, JP

FUJII, Gen

Tokyo 104-0045, JP

Il register numna mintga partida cun num ed adressa. In possessur u in represchentant vegn collià cun in’organisaziun, sch’exact ina unitad giuridica dal register da commerzi porta ses num; la via d’ina partida betg enconuschida uschia na vegn betg mussada qua.